5 Best Performing Healthcare Stocks So Far in 2026

4. Enliven Therapeutics, Inc. (NASDAQ:ELVN)

YTD Share Price Gain: 167.5%

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the best performing healthcare stocks so far in 2026. On April 30, Mizuho reaffirmed an Outperform rating on Enliven Therapeutics, Inc. (NASDAQ:ELVN), setting a price target of $45. The rating update came after Merck noted during its fiscal Q1 earnings call that it believes Terns’ TERN-701 major molecular response “will be north of 50% and within the confidence interval as had been publicly stated.” The firm believes the comments to be a positive for ELVN-001, adding that today’s “high-level quantification” only further supports the significant degradation.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) also received a rating update from Clear Street on April 27. The firm lifted the price target on the stock to $55 from $36, maintaining a Buy rating on the shares. The firm stated that it left meetings with management with increased conviction in ELVN-001 as a differentiated ATP-site binder for BCR-ABL1. For additional reference, Enliven Therapeutics, Inc. (NASDAQ:ELVN) reported in fiscal Q4 and full year 2025 earnings that it has a strong balance with $463 million in cash, cash equivalents, and marketable securities, which is anticipated to provide cash runway into the first half of 2029.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is a clinical-stage biopharmaceutical company with a focus on the discovery and development of small-molecule therapeutics. The company’s pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002.